|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.14 USD | +0.92% |
|
+0.58% | -4.58% |
| 01-20 | Global drugmakers rush to boost US presence as tariff threat looms | RE |
| 01-20 | Berenberg Lifts Price Target on AbbVie to $275 From $270, Keeps Buy Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 382B | |||||
| 966B | |||||
| 525B | |||||
| 371B | |||||
| 278B | |||||
| 276B |
- Stock Market
- Equities
- ABBV Stock
- Charts AbbVie Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition